Biohaven Ltd (BHVN)

$13.82 +0.39 (2.90%)
Market Cap 2.07B
Revenue (ttm) 0.00
Net Income (ttm) -738.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.87
Volume 1,242,580
Avg Vol 3,127,654
Day's Range N/A - N/A
Shares Out 150.56M
Stochastic %K 6%
Beta 1.28
Analysts Strong Sell
Price Target $22.75

Company Profile

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinica...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 404 0410
Address:
215 Church Street, New Haven, United States
Timefortendies77
Timefortendies77 Jul. 30 at 12:31 PM
$BHVN The extra boost we got from CAPR and REPL has been mostly erased at this point, decreasing likelihood of the BVHN SCA drug getting a reassessment. FDA APPEARED to be flexible now, and "mending bridges" but the staffers brought the hammer down on CAPR and REPL (rare disease drugs). Since we know BHVN SCA drug was rejected last year, all analysts took it out of the models---and other rare disease drugs still face issues --we can all just move on and get ready for the fall fireworks with OBESITY and EPILEPSY (the real catalysts for this year). Holding strong and appreciated the buying opportunity.
1 · Reply
Timefortendies77
Timefortendies77 Jul. 29 at 4:27 PM
$BHVN More buying opportunity.
0 · Reply
Cache_Money
Cache_Money Jul. 29 at 7:59 AM
$BHVN Been looking for companies with novel MoA’s and Biohaven has my attention right now. Despite being behind Azetukalner in trial timelines, Opakalim has GABA activity completely dialed out and strict specificity for the Kv7.2/Kv7.3 channel complex, meaning no somnolence and thus superior safety/tolerability. Taldefgrobep alfa as a GLP-1-independent monotherapy also seems like it would have a decent niche and also has an exceptional safety profile. Their IgG degrader is interesting too and looks like it compares favorably to FcRN modalities. This company has made some excellent choices for its pipeline.
1 · Reply
OnlyEverLong
OnlyEverLong Jul. 28 at 4:57 PM
$BHVN Major setbacks for both $CAPR and $REPL challenge the thesis that FDA leadership has fundamentally shifted with regard to paths forward for previous rejected rare disease treatments, raising some doubts surrounding a potential reassessment for troriluzole. During circumstances like this, it's helpful to have an experienced team like Biohaven that can be trusted to make prudent decisions for shareholders which could explain why no news related to this has come out. Haven't given up on this completely, but definitely taking solace in the fact that $BHVN has such a diverse pipeline and there are concrete major catalysts approaching.
2 · Reply
SYNSTER187
SYNSTER187 Jul. 28 at 3:45 PM
$BHVN How did a 7% pre-market gain to $15.51 get deleted the minute the market opened?
0 · Reply
topstockalerts
topstockalerts Jul. 27 at 8:14 PM
Biohaven shares rose in afternoon trading, supported by positive momentum from a landmark federal jury verdict that upheld the company's exclusive rights to Yale University's MODA targeted protein degradation platform. The ruling found Avilar Therapeutics and RA Capital Management had willfully misappropriated trade secrets and awarded Biohaven and Yale $4 million in damages. The decision strengthens Biohaven's intellectual property position around its extracellular protein degradation programs, including BHV-1300 for Graves' disease and BHV-1400 for IgA nephropathy. Investors are also looking ahead to key clinical catalysts, including Phase 2/3 RISE3 epilepsy data for opakalim and Phase 2 obesity trial results for taldefgrobep alfa, both expected in the second half of 2026. Analysts remain broadly bullish, with consensus price targets well above current levels. $BHVN
0 · Reply
Timefortendies77
Timefortendies77 Jul. 22 at 1:37 PM
$BHVN Trial result expectations based on all available known information--Epilepsy Nov/DEC, Obesity October. So we have the wild card first and the higher probability later. Will be quite the year!
3 · Reply
Timefortendies77
Timefortendies77 Jul. 22 at 12:42 AM
$BHVN Total Lobbying spend 2025-240K, 2026-380k. Total spend since Kyle D started at FDA-180k. Note all the money in 2026 before Kyle was to try to get FDA to listen and find a path forward on the SCA drug which was not able to happen so they gave up, worked with a group to appeal to the T Admini and the FDA Admin got replaced. Since then 4 Rare Disease drugs that were struck down last year have found paths forward. Is our T SCA drug next?
1 · Reply
Timefortendies77
Timefortendies77 Jul. 22 at 12:20 AM
$BHVN Got to love it--up 50 cents, then down 50 cents after hours. Seems pinned around high 14s, low 15s now until news.
0 · Reply
JFais
JFais Jul. 21 at 2:43 PM
$VYNE (NP) 1 for 50 reverse split, merging with Yarrow Bioscience $200M financing led by RTW with other key funds participating (OrbiMed, venBio, Logos, Perceptive, etc) New lead = mAb targeting TSHR for Grave's disease and TED. Pretty early-stage though (phase 1b data expected 1H 27), China partner GenSci already in phase 1 Makes me think of $BHVN (TSHR degrader already in phase 3 & receiving little to no credit)
1 · Reply
Latest News on BHVN
Biohaven and Yale University awarded $4M in trade secret verdict

2026-07-27T11:11:53.000Z - 3 days ago

Biohaven and Yale University awarded $4M in trade secret verdict

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

Jul 27, 2026, 7:00 AM EDT - 3 days ago

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

Biohaven reports new data on BHV-1530

2026-07-20T11:35:41.000Z - 10 days ago

Biohaven reports new data on BHV-1530

Biohaven enters into clinical supply agreement with Regeneron

2026-07-20T11:35:36.000Z - 10 days ago

Biohaven enters into clinical supply agreement with Regeneron

REGN

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Jul 20, 2026, 7:30 AM EDT - 10 days ago

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Biohaven’s Bruce Car retires as chief scientific officer

2026-07-09T21:05:16.000Z - 21 days ago

Biohaven’s Bruce Car retires as chief scientific officer

Biohaven Announces Scientific Leadership Transitions

Jul 9, 2026, 5:00 PM EDT - 21 days ago

Biohaven Announces Scientific Leadership Transitions

Biohaven announces completion of enrollment in RISE3 trial

2026-06-30T11:35:53.000Z - 4 weeks ago

Biohaven announces completion of enrollment in RISE3 trial

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

Jun 30, 2026, 7:30 AM EDT - 4 weeks ago

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

Biohaven falls -9.8%

2026-06-29T14:05:29.000Z - 4 weeks ago

Biohaven falls -9.8%

Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease

2026-06-29T11:35:56.000Z - 4 weeks ago

Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

Jun 29, 2026, 7:30 AM EDT - 4 weeks ago

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

Biohaven downgraded to Underperform from Neutral at BofA

2026-06-29T10:20:18.000Z - 4 weeks ago

Biohaven downgraded to Underperform from Neutral at BofA

XENE

Biohaven rises 7.4%

2026-06-26T14:07:04.000Z - 4 weeks ago

Biohaven rises 7.4%

Biohaven price target raised to $20 from $15 at Deutsche Bank

2026-06-26T12:35:29.000Z - 4 weeks ago

Biohaven price target raised to $20 from $15 at Deutsche Bank

Biohaven initiates first-in-human dosing for BHV-8100

2026-06-01T11:42:14.000Z - 2 months ago

Biohaven initiates first-in-human dosing for BHV-8100

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

Jun 1, 2026, 7:30 AM EDT - 2 months ago

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

Biohaven’s candidates in Graves’ Disease and IgA nephropathy shows efficacy

2026-05-27T12:22:09.000Z - 2 months ago

Biohaven’s candidates in Graves’ Disease and IgA nephropathy shows efficacy

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

May 27, 2026, 7:30 AM EDT - 2 months ago

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

Biohaven reports data from selective Kv7.2/7.3 channel activator program

2026-05-26T12:55:10.000Z - 2 months ago

Biohaven reports data from selective Kv7.2/7.3 channel activator program

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

May 26, 2026, 7:30 AM EDT - 2 months ago

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

Biohaven price target lowered to $18 from $21 at Morgan Stanley

2026-05-13T16:59:45.000Z - 2 months ago

Biohaven price target lowered to $18 from $21 at Morgan Stanley

Biohaven price target lowered to $22 from $23 at RBC Capital

2026-05-05T12:31:27.000Z - 3 months ago

Biohaven price target lowered to $22 from $23 at RBC Capital

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

May 4, 2026, 4:02 PM EDT - 3 months ago

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven Quarterly report: Q1 2026

May 4, 2026, 4:00 PM EDT - 3 months ago

Biohaven Quarterly report: Q1 2026

Biohaven Earnings release: Q1 2026

May 4, 2026, 4:00 PM EDT - 3 months ago

Biohaven Earnings release: Q1 2026

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Mar 19, 2026, 7:30 AM EDT - 4 months ago

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven Proxy statement: Proxy Filing

Mar 13, 2026, 8:00 AM EDT - 4 months ago

Biohaven Proxy statement: Proxy Filing

Biohaven Proxy statement: Proxy Filing

Mar 13, 2026, 8:00 AM EDT - 4 months ago

Biohaven Proxy statement: Proxy Filing

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 4:05 PM EST - 5 months ago

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven Annual report: Q4 2025

Mar 2, 2026, 4:00 PM EST - 5 months ago

Biohaven Annual report: Q4 2025

Biohaven Earnings release: Q4 2025

Mar 2, 2026, 4:00 PM EST - 5 months ago

Biohaven Earnings release: Q4 2025

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 7 months ago

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Biohaven Slides: 44th Annual J.P. Morgan Healthcare Conference presentation

Jan 12, 2026, 7:00 AM EST - 7 months ago

Biohaven Slides: 44th Annual J.P. Morgan Healthcare Conference presentation

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Jan 7, 2026, 7:00 AM EST - 7 months ago

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Biohaven's depression drug fails mid-stage trial, shares fall

Dec 24, 2025, 3:24 PM EST - 7 months ago

Biohaven's depression drug fails mid-stage trial, shares fall

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Dec 24, 2025, 1:00 PM EST - 7 months ago

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

Dec 11, 2025, 7:00 AM EST - 8 months ago

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

Nov 13, 2025, 4:05 PM EST - 9 months ago

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

Nov 12, 2025, 7:15 AM EST - 9 months ago

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

Biohaven Announces Proposed Public Offering of Common Shares

Nov 11, 2025, 4:05 PM EST - 9 months ago

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Biohaven Quarterly report: Q3 2025

Biohaven Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Biohaven Earnings release: Q3 2025

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

Nov 10, 2025, 6:58 AM EST - 9 months ago

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

Biohaven shares plunge after US FDA declines to approve brain disorder drug

Nov 5, 2025, 10:02 AM EST - 9 months ago

Biohaven shares plunge after US FDA declines to approve brain disorder drug

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Nov 4, 2025, 8:06 PM EST - 9 months ago

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Biohaven Slides: Corporate Presentation

Aug 12, 2025, 8:00 PM EDT - 1 year ago

Biohaven Slides: Corporate Presentation

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Biohaven Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Biohaven Quarterly report: Q2 2025

Biohaven Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Biohaven Earnings release: Q2 2025

Law Offices of Frank R. Cruz Encourages Biohaven Ltd.

Jul 18, 2025, 12:06 PM EDT - 1 year ago

Law Offices of Frank R. Cruz Encourages Biohaven Ltd.

Law Offices of Howard G. Smith Encourages Biohaven Ltd.

Jul 18, 2025, 12:00 PM EDT - 1 year ago

Law Offices of Howard G. Smith Encourages Biohaven Ltd.

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. (BHVN)

Jul 15, 2025, 10:46 AM EDT - 1 year ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. (BHVN)

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

Jun 10, 2025, 2:00 PM EDT - 1 year ago

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

Timefortendies77
Timefortendies77 Jul. 30 at 12:31 PM
$BHVN The extra boost we got from CAPR and REPL has been mostly erased at this point, decreasing likelihood of the BVHN SCA drug getting a reassessment. FDA APPEARED to be flexible now, and "mending bridges" but the staffers brought the hammer down on CAPR and REPL (rare disease drugs). Since we know BHVN SCA drug was rejected last year, all analysts took it out of the models---and other rare disease drugs still face issues --we can all just move on and get ready for the fall fireworks with OBESITY and EPILEPSY (the real catalysts for this year). Holding strong and appreciated the buying opportunity.
1 · Reply
Timefortendies77
Timefortendies77 Jul. 29 at 4:27 PM
$BHVN More buying opportunity.
0 · Reply
Cache_Money
Cache_Money Jul. 29 at 7:59 AM
$BHVN Been looking for companies with novel MoA’s and Biohaven has my attention right now. Despite being behind Azetukalner in trial timelines, Opakalim has GABA activity completely dialed out and strict specificity for the Kv7.2/Kv7.3 channel complex, meaning no somnolence and thus superior safety/tolerability. Taldefgrobep alfa as a GLP-1-independent monotherapy also seems like it would have a decent niche and also has an exceptional safety profile. Their IgG degrader is interesting too and looks like it compares favorably to FcRN modalities. This company has made some excellent choices for its pipeline.
1 · Reply
OnlyEverLong
OnlyEverLong Jul. 28 at 4:57 PM
$BHVN Major setbacks for both $CAPR and $REPL challenge the thesis that FDA leadership has fundamentally shifted with regard to paths forward for previous rejected rare disease treatments, raising some doubts surrounding a potential reassessment for troriluzole. During circumstances like this, it's helpful to have an experienced team like Biohaven that can be trusted to make prudent decisions for shareholders which could explain why no news related to this has come out. Haven't given up on this completely, but definitely taking solace in the fact that $BHVN has such a diverse pipeline and there are concrete major catalysts approaching.
2 · Reply
SYNSTER187
SYNSTER187 Jul. 28 at 3:45 PM
$BHVN How did a 7% pre-market gain to $15.51 get deleted the minute the market opened?
0 · Reply
topstockalerts
topstockalerts Jul. 27 at 8:14 PM
Biohaven shares rose in afternoon trading, supported by positive momentum from a landmark federal jury verdict that upheld the company's exclusive rights to Yale University's MODA targeted protein degradation platform. The ruling found Avilar Therapeutics and RA Capital Management had willfully misappropriated trade secrets and awarded Biohaven and Yale $4 million in damages. The decision strengthens Biohaven's intellectual property position around its extracellular protein degradation programs, including BHV-1300 for Graves' disease and BHV-1400 for IgA nephropathy. Investors are also looking ahead to key clinical catalysts, including Phase 2/3 RISE3 epilepsy data for opakalim and Phase 2 obesity trial results for taldefgrobep alfa, both expected in the second half of 2026. Analysts remain broadly bullish, with consensus price targets well above current levels. $BHVN
0 · Reply
Timefortendies77
Timefortendies77 Jul. 22 at 1:37 PM
$BHVN Trial result expectations based on all available known information--Epilepsy Nov/DEC, Obesity October. So we have the wild card first and the higher probability later. Will be quite the year!
3 · Reply
Timefortendies77
Timefortendies77 Jul. 22 at 12:42 AM
$BHVN Total Lobbying spend 2025-240K, 2026-380k. Total spend since Kyle D started at FDA-180k. Note all the money in 2026 before Kyle was to try to get FDA to listen and find a path forward on the SCA drug which was not able to happen so they gave up, worked with a group to appeal to the T Admini and the FDA Admin got replaced. Since then 4 Rare Disease drugs that were struck down last year have found paths forward. Is our T SCA drug next?
1 · Reply
Timefortendies77
Timefortendies77 Jul. 22 at 12:20 AM
$BHVN Got to love it--up 50 cents, then down 50 cents after hours. Seems pinned around high 14s, low 15s now until news.
0 · Reply
JFais
JFais Jul. 21 at 2:43 PM
$VYNE (NP) 1 for 50 reverse split, merging with Yarrow Bioscience $200M financing led by RTW with other key funds participating (OrbiMed, venBio, Logos, Perceptive, etc) New lead = mAb targeting TSHR for Grave's disease and TED. Pretty early-stage though (phase 1b data expected 1H 27), China partner GenSci already in phase 1 Makes me think of $BHVN (TSHR degrader already in phase 3 & receiving little to no credit)
1 · Reply
black_fox
black_fox Jul. 21 at 1:20 PM
$BHVN still no sca news
0 · Reply
Timefortendies77
Timefortendies77 Jul. 20 at 8:57 PM
$BHVN Lobbying numbers just came in and they have been spending--big amounts this month --looks like rare disease lobbying most likely linked to still trying to push through the SCA T drug.
1 · Reply
boomer21
boomer21 Jul. 20 at 5:43 PM
$BHVN thought this would have been good
1 · Reply
BapoRothstein
BapoRothstein Jul. 20 at 4:43 PM
$BHVN Market often front-runs data in either direction on pre-approval names. It’s called an 18-month *forward* discounting mechanism for a reason. Hilarious to me that so many bulls around here are so quick to accuse me, directly or indirectly, of being stupid/illogical for pressing for a mid PT on a companies of this caliber and pipeline potential. It’s almost as if they are scared I might upset their retarded little tweaker plans of trying to perfectly time their trades here. Sorry bruvs, the market isn’t going to wait around for your retarded trading schedules. It can easily move violently, doubling or getting cut in half, in a few days, seemingly on no news, out of nowhere, way in advance of any official data release. Call me stupid all you want. It won’t change the reality of the situation. Tweaker putos always lose. There is no shortcut or magic trick that will ever beat staying fully invested in a promising pre-approval company through all the apparent “no-news” periods.
2 · Reply
OnlyEverLong
OnlyEverLong Jul. 20 at 12:09 PM
$BHVN https://www.prnewswire.com/news-releases/biohaven-to-present-new-clinical-data-at-esmo-congress-on-bhv-1530-a-novel-fgfr3-directed-adc-with-a-proprietary-topoisomerase-i-topoix-payload-302829238.html
1 · Reply
stockpicker63
stockpicker63 Jul. 19 at 3:21 PM
$BHVN Biohaven Ltd Bullish Setup TA and AI Analysis
0 · Reply
SuperGreenToday
SuperGreenToday Jul. 18 at 4:19 PM
$BHVN Share Price: $15.43 Contract Selected: Jan 15, 2027 $15 Calls Buy Zone: $2.72 – $3.36 Target Zone: $4.85 – $5.93 Potential Upside: 69% ROI Time to Expiration: 180 Days | Updates via https://fxcapta.com/stockinfo/
1 · Reply
JackDarwin
JackDarwin Jul. 18 at 9:19 AM
$BHVN Bullish Engulfing with good volume.
0 · Reply
BapoRothstein
BapoRothstein Jul. 18 at 1:29 AM
$BHVN shocked and appalled that this isn’t at 40 yet. Wild!
2 · Reply
Timefortendies77
Timefortendies77 Jul. 17 at 10:53 PM
$BHVN Today was share buying along with short term options mechanics. Expect as normal the surge will fade and the process will begin again after shorts get exhausted.
0 · Reply
OnlyEverLong
OnlyEverLong Jul. 17 at 9:38 PM
$BHVN so we end with a nice green hammer on the weekly. Not bad. Encouraging to see the higher volume days correlated with moves higher and relatively weak volume on the down days. TBH, I'm actually pleasantly surprised it's held onto this range considering there's been no news (yet 🤞).
0 · Reply
Timefortendies77
Timefortendies77 Jul. 17 at 8:44 PM
$BHVN So the July guy did not get the FDA SCA drug reeval right, this goes to show chasing blind massive Unusual Trades is a fools game unlesss you understand exactly what is happening. And now we are into Aug, Sept, Oct, Jan, and Jan options left on the board.
0 · Reply